GeneDx Holdings (WGS)

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

De GeneDx Holdings Corp. Class A Common Stock (WGS) aandelenkoers vandaag is , wat een NaN% beweging weergeeft sinds de markt geopend. De marktkapitalisatie van het bedrijf staat op $ 2,18 mld., met een dagelijks tradevolume van aandelen. De vorige slotkoers was .

Klaar om aan de slag te gaan? Volg de onderstaande stappen, of lees onze gids over hoe je GeneDx Holdings aandelen op Kraken kunt kopen vanaf € 10.